|1.||Schmitz, G: 4 articles (02/2010 - 02/2000)|
|2.||Wang, Qi: 3 articles (01/2015 - 03/2014)|
|3.||Yin, Yan-Wei: 2 articles (01/2015 - 01/2014)|
|4.||Gebre, Abraham K: 2 articles (11/2012 - 05/2005)|
|5.||Parks, John S: 2 articles (11/2012 - 05/2005)|
|6.||Wu, Zhi-Ying: 2 articles (07/2012 - 04/2010)|
|7.||Tang, Chongren: 2 articles (03/2012 - 07/2009)|
|8.||Zuckerman, S H: 2 articles (05/2001 - 06/2000)|
|9.||Panousis, C G: 2 articles (05/2001 - 06/2000)|
|10.||Langmann, T: 2 articles (04/2001 - 02/2000)|
01/01/2014 - "Influence of ATP-binding cassette transporter 1 R219K and M883I polymorphisms on development of atherosclerosis: a meta-analysis of 58 studies."
01/01/2015 - "ATP-binding cassette transporter 1 C69T and V825I polymorphisms in the development of atherosclerosis: a meta-analysis of 18,320 subjects."
01/01/2014 - "Numerous epidemiological studies have evaluated the associations between ATP-binding cassette transporter 1 (ABCA1) R219K (rs2230806) and M883I (rs4149313) polymorphisms and atherosclerosis (AS), but results remain controversial. "
05/01/2015 - "Thus, via effects on both ABCA1-expressing cells and circulating HDL function, the inhibition of ABCA1 protein degradation by IMM-H007 promotes HDL cholesterol efflux capacity and RCT and attenuates atherogenesis. "
05/01/2015 - "Inhibition of ABCA1 protein degradation promotes HDL cholesterol efflux capacity and RCT and reduces atherosclerosis in mice."
|2.||Coronary Disease (Coronary Heart Disease)
07/01/2005 - "To study the distribution of R219K polymorphism in ATP-Binding Cassette Transporter 1 (ABCA1) gene in Chinese Han population and the association of this polymorphism with coronary heart disease (CHD) . "
07/01/2005 - "[Relationship between the R219K polymorphism of ATP-binding cassette transporter 1 gene and coronary heart disease]."
04/01/2003 - "The association of the R219K polymorphism in the ATP-binding cassette transporter 1 ( ABCA1) gene with coronary heart disease and hyperlipidaemia."
02/15/2001 - "Common variants in the gene encoding ATP-binding cassette transporter 1 in men with low HDL cholesterol levels and coronary heart disease."
04/01/2003 - "The R219K polymorphism in the ATP-binding cassette transporter 1 gene ( ABCA1) has been associated with reduced severity of atherosclerosis, fewer coronary events, decreased triglycerides and a trend to increased HDL in men with coronary heart disease (CHD). "
07/01/2008 - "Here, we show that severe hyperthyroidism in mice did not affect hepatic expression of scavenger receptor class B, type I, but reduced hepatic expression of ATP-binding cassette transporter 1, accompanied by a 40% reduction of HDL-C. "
07/01/2008 - "The sterol content of bile, liver, and feces was markedly increased, accompanied by up-regulation of hepatic cholesterol 7alpha-hydroxylase, and ATP-binding cassette transporter 5, which is known to promote biliary sterol secretion upon dimerization with ATP-binding cassette transporter 8. Both control and hyperthyroid mice exerted identical plasma clearance of iv injected [(3)H]HDL-C, supporting the view that severe hyperthyroidism does not affect HDL-C clearance but, rather, its formation via hepatic ATP-binding cassette transporter 1."
02/01/2010 - "Normal human breast tissue, breast cancer cell lines, and 162 tumor samples of patients with primary unilateral invasive breast cancer were analyzed for ABCA3 and ABCA1 protein expression by immunohistochemistry using tissue microarrays. "
09/01/2012 - "In our previous study, we demonstrated that lycopene can inhibit the proliferation of androgen-dependent prostate LNCaP cancer cells through the activation of the peroxisome proliferator-activated receptor gamma (PPARγ)-liver X receptor alpha (LXRα)-ATP-binding cassette transporter 1 (ABCA1) pathway. "
01/01/2014 - "Further study indicated that hyperglycemia could significantly inhibit mRNA levels of Lxrb (P=0.0002), small heterodimer partner 1 (Shp1) (P<0.0001), liver receptor homologue-1 (Lrh1) (P=0.0012), ATP-binding cassette transporter 1 (Abca1) (P=0.0012) and Pparb/d (P=0.0043). "
01/01/2015 - "Further investigation revealed that the antagonistic effect on hyperlipidemia and lipid ectopic deposition was related to lowering the lipid synthesis pathway (de novo pathway, 3-hydroxy-3-methyl glutaryl coenzyme A reductase (HMG-CoAR)), promoting fatty acid oxidation [peroxisome proliferator-activated receptor-alpha (PPARα), carnitine palmitoyltransferase-1, etc.] and increasing cholesterol output (PPARγ-liver X receptor-α-ATP-binding cassette transporter-1); the inhibitory effects on inflammation and hyperglycemia were mediated by blocking inflammatory genes activation and reducing gluconeogenic genes expression (phosphoenolpyruvate carboxykinase and G6Pase). "
|1.||Adenosine Triphosphate (ATP)
|3.||Cholesterol 7-alpha-Hydroxylase (Cholesterol 7 alpha Hydroxylase)
|5.||Apolipoprotein A-I (Apolipoprotein A1)
|6.||Messenger RNA (mRNA)
|7.||liver X receptor